Oramed Pharmaceuticals
ORMP
22 hedge funds and large institutions have $13.7M invested in Oramed Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
4% less funds holding
Funds holding: 23 → 22 (-1)
10% less capital invested
Capital invested by funds: $15.3M → $13.7M (-$1.58M)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
62% less call options, than puts
Call options by funds: $211K | Put options by funds: $557K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$1.66M |
| 2 |
D.E. Shaw & Co
New York
|
+$225K |
| 3 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$174K |
| 4 |
GIM
Greylin Investment Management
Orange,
Virginia
|
+$64.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$528K |
| 2 |
Jane Street
New York
|
-$176K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$142K |
| 4 |
Morgan Stanley
New York
|
-$132K |
| 5 |
Barclays
London,
United Kingdom
|
-$121K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Barclays
London,
United Kingdom
| – | -$121K | -10,989 | Closed |
|
27
AllianceBernstein
Nashville,
Tennessee
| – | -$1K | -55 | Closed |
|
ORMP Hedge Fund Activity: Q2 2014 in Review
22 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2014, worth a combined $13.7M — down 10% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORMP and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Stifel Financial, adding an estimated $1.66M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $528K sold.
- 22 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2014, down from 23 in Q1 2014.
- Funds reported $13.7M of Oramed Pharmaceuticals stock for Q2 2014, down 10% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q2 2014 and 6 closed out, a net change of -1 holder.
- The largest Oramed Pharmaceuticals buyer in Q2 2014 was Stifel Financial, an estimated $1.66M added.
- The largest Oramed Pharmaceuticals seller in Q2 2014 was Columbus Circle Investors, an estimated $528K sold.
Based on aggregated 13F filings for Q2 2014.